From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease

Last Updated: Friday, September 15, 2023

According to data from a cross-sectional chronic GVHD natural history study, history of cyclosporine use (OR 2.19, 95% CI: 1.13-4.25), angiotensin receptor blocker use (OR 5.57, 95% CI: 1.49-20.84), proteinuria (OR 2.39, 95% CI: 1.19-4.79), lower C-reactive protein (OR 0.95, 95% CI: 0.91-0.99), lower C3 (OR 0.98, 95% CI: 0.97-0.99), and lower hemoglobin (OR 0.70, 95% CI: 0.58-0.84) were jointly associated with kidney dysfunction. Further, overall survival was lower in those patients with moderate-severe kidney dysfunction (P = 0.015).

Bone Marrow Transplantation
Advertisement
News & Literature Highlights

Targeted Oncology

Acute GVHD responds quickly to itolizumab treatment in phase 1b trial

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Journal of Clinical Oncology

Naive T-cell depletion to prevent chronic graft-versus-host disease

Blood

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

The ASCO Post

Abatacept for prophylaxis of acute graft-vs-host disease

Translation and Cellular Therapy

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Blood

Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo

Translation and Cellular Therapy

Impact of conditioning regimen and graft-versus-host disease prophylaxis on the outcome of haploidentical peripheral blood stem cell transplantation for high-risk severe aplastic anaemia in children and young adults

Journal of Clinical Oncology

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

2022 ASH Annual Meeting

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following alloHCT

Advertisement
Advertisement